SGK1 and long QT syndrome 3: A proof of concept for SGK1-inhibition as a therapy for LQT3 was provided by Bezzerides et al, who demonstrated an APD-shortening effect in patient-specific LQT3 hiPSC-CMs by SGK1-inhibitors [29].